The US FDAâs EIR is received for the drug-device combination to be commercialised from the Stelis Pharma#39;s flagship facility in Bengaluru, Indiafrom Moneycontrol Business News https://ift.tt/MLtfcZX
The US FDAâs EIR is received for the drug-device combination to be commercialised from the Stelis Pharma#39;s flagship facility in Bengaluru, India
Comments
Post a Comment